VA Finds Paxlovid Can Address Risk of Long COVID

Pre-peer review study included more than 56,000 veterans.

The Department of Veterans Affairs released a preliminary study called “Nirmatrelvir and the risk of post-acute sequelae of COVID-19”. The study, conducted by VA researcher Dr. Ziyad Al-Aly, conducted tests on more than 56,000 veterans with COVID-19 and found that 25 percent of veterans given the oral antiviral medication Paxlovid had significantly decreased symptoms of Long COVID after their initial infection. Though the study has not yet been peer-reviewed, the VA opted to release the study “in the interest of public health.”

“This groundbreaking study is going to improve the lives of Veterans and all Americans,” said Secretary Denis McDonough. “VA’s researchers have conducted life-saving studies throughout the pandemic, and Dr. Al-Aly’s excellent work here is yet another example of VA leading the way.”

As the Lord Leads, Pray with Us…

  • For Secretary McDonough to seek God’s leading as he heads the VA.
  • For wisdom for researchers as they seek cures and solutions to covid and other maladies.
  • For the president and his health advisors as they continue to pursue measures to address the coronavirus and its variants.

Sources: Department of Veterans Affairs


Back to top